Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bristol Myers Squibb International Corporation
Femme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects with Triple Negative (ER, PR, Her2 negative) Locally Advanced non-resectable and/or Metastatic Breast Cancer Revised protocol 01 to incorporate protocol amendment 01
To estimate the response rate of ixabepilone monotherapy, and the combination of ixabepilone plus cetuximab as first-line treatment of female subjects with triple negative (ER, PR, Her2 negative) loca...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific-Site (version 1.0, dated 17-Dec-08)
To determine if apixaban is superior to placebo for preventing the composite of cardiovascular death, myocardial infarction, or ischemic stroke in subjects with recent ACS.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who are Resistant or Intolerant to Imatinib Mesylate. Revised Protocol 06, incorporating Administrative Letters 01, 02, 03, 04 and 05 and Amendments 01, 02, 03, 04 and 05 (version 1.0, dated 14-Sep-2010)
To compare the efficacy of BMS-354825 as defined by MCyR when administered QD relative to BMS-354825 administered BID in the treatment of CP CML imatinib-resistant subjects. The QD schedule will be co...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody
The primary objective of this trial are: - To determine the incidence of high-grade (CTCAE v4.0 Grade 3 or higher), treatment related, select adverse events in patients with histologically confirme...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients with Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine With Placebo. Revised Protocol 04, Incorporates Administrative Letters 01, 02 & 03, Amendment 02, Amendment 06 and Amendment 07. Revised Protocol 06 incorporating Administrative letters 01, 02 & 03, Amendments 02, 06, 07, 08 and 09
To compare OS in patients with previously untreated Stage IIIc, N3 (unresectable) or Stage IV melanoma receiving dacarbazine plus 10mg/kg ipilimumab vs. dacarbazine with Placebo.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Patients with Type 2 Diabetes with not very well controlled high blood pressure taking medicine called Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB). The Phase 3 Trial is carried out at several sites and neither patients nor doctors know to which study treatment (medication in different strength or dummy treatment) they are randomly assigned
To compare the change from baseline in seated systolic blood pressure after 12 weeks of double-blind treatment between 10 mg dapagliflozin treatment group and the placebo treatment group. • To comp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with Rheumatoid Arthritis Having an Inadequate Response to Methotrexate. Pharmacogenetics Blood Sample Amendment 01 (version 1.0, dated 19-Dec-2007); Revised Protocol 01, incorporating administrative letter 01 and amendment 03 (version 1.0, dated 12-Mar-2008)
To assess the clinical efficacy of BMS-582949 at a dose of 300 mg once a day (qd) compared to placebo at 12 weeks as measured by ACR 20 in subjects with RA who are on background therapy with MTX.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment with Aripiprazole in Patients with Schizophrenia Revised Protocol 01, incorporating Amendment 03 + Pharmacogenetics Blood Sample Amendment 01 - Site Specific (Version 1.0, Dated 2005-10-03)
To evaluate the effect on patient weight of adjunctive therapy of aripiprazole with clozapine versus clozapine mono-therapy, in schizophrenic patients who are not optimally controlled on clozapine.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
Study to compare the effect of ipilimumab retreatment with chemotherapy in advanced melanoma
The purpose of the study is to compare the 18-month overall survival rate in subjects with advanced melanoma receiving ipilimumab monotherapy (3 mg/kg) as retreatment versus chemotherapy of investigat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Phase II Study of Dasatinib BMS-354825 for Androgen-Deprived Progressive Prostate Cancer
Using an individual dose-ranging approach, to estimate the PSA response rate of adding dasatinib to ongoing androgen deprivation with Luteinizing Hormone Releasing Hormone LHRH treatment or surgical...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant